With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.62937-45-5,D-Prolinamide,as a common compound, the synthetic route is as follows.,62937-45-5
[01 1 18] Step 2 : (R)-6-(4-((2-carbamoylpyrrolidin- 1 -yl)methyl)phenyl)- 1 -cyclopentyl-N- ((4,6-dimethyl -2-oxo- 1 ,2-dihydropyridin-3-yl)methy 1)- 1 H-indazole-4-carboxamide [01 1 19] To a stirred solution of 1 -cyclopentyl-N-((4,6-dimethyl-2-oxo- 1 ,2-dihydropyridin- 3-yl)methyl)-6-(4-formylphenyl)-l H-indazole-4-carboxamide (0.175 g, 0.373 mmol) in methanol (3 mL) acetic acid (0.022 g, 0.373 mmol) and respective amine [[[amine quantity?]]] was added, resulting reaction mass was stirred at room temperature for 4 h. To this reaction mixture sodium cyanoborohydride (0.028 g, 0.448 mmol) was added at cooling condition and reaction mixture was stirred at room temperature for 48 h. On completion solvent was removed under reduced pressure and water was added to it, and then extracted with 10% MeOH/DCM. Combined organic layers were washed with water, dried over anhydrous Na2S04, filtered and concentrated under reduced pressure to afford crude. The crude was purified by prep HPLC affording desired compound as TFA salt (12.3% yield). LCMS: 567.30 (M + 1)+; HPLC: 97.31% (@ 254 nm) (R,;5.366); NMR (OMSO-d6, 400 MHz) 6 1 1.52 (s, I H), 9.71 (s, I H), 8.64 (t, I H, J=4.4 Hz), 8.37 (s, IH), 8.17 (s, IH), 7.94- 7.97 (m, 3H), 7.87 (s, IH), 7.61-7.67 (m, 3H), 5.89 (s, lH), 5.31-5.38 (m, I H), 4.38-4.45 (m, 4H), 4.41 -4.13 (m, I H), 3.32 (2H merged in solvent peak), 2.22 (s, 3H), 2.14-2.21 (m, 3H), 2.12 (s, 3H), 1.82-2.08 (m, 7H), 1.70-1.72 (m, 2H).
62937-45-5 D-Prolinamide 447554, acatalyst-ligand compound, is more and more widely used in various fields.
Reference£º
Patent; EPIZYME, INC.; KUNTZ, Kevin, Wayne; OLHAVA, Edward, James; CHESWORTH, Richard; DUNCAN, Kenneth, William; WO2012/118812; (2012); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI